La Repubblica news article

We are proud to share that EVis Bioscience has been featured in la Repubblica‘s “Lab Revolution” series, highlighting our innovative approach to gene therapy for rare diseases.

Founded in June 2024 by Italian researchers Elita Montanari with investor Tommaso Caselli, EVis Bioscience is a spin-off from ETH Zurich. Our mission is to develop next-generation non-viral vectors capable of delivering therapeutic RNA directly to specific organs, offering hope for patients with rare genetic disorders.

Dr. Montanari’s journey—from her studies in Chemistry and Pharmaceutical Technology at Sapienza University of Rome to research roles in Manchester, Paris, and Zurich—culminated in the conception of a novel RNA delivery system during the COVID-19 pandemic. Unlike traditional lipid nanoparticles used in vaccines, our technology aims for precise targeting, enhancing treatment efficacy and safety.

This recognition by la Repubblica underscores the potential impact of our work in the field of rare diseases.

➡️ Read the full article (in Italian) here:

Italian Researchers Seeking a Cure for Rare Diseases – la Repubblica